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In this multicenter, open-label, randomized controlled trial,
we determined whether 2-month prednisolone therapy for
steroid-sensitive nephrotic syndrome was inferior or not to
6-month therapy despite significantly less steroid exposure.
The primary end point was time from start of initial treatment
to start of frequently relapsing nephrotic syndrome. The pre-
specified non-inferiority margin was a hazard ratio of 1.3 with
one-sided significance of 5%. We randomly assigned 255
children with an initial episode of steroid-sensitive nephrotic
syndrome to either 2 - or 6-month treatment of which 246
were eligible for final analysis. The total prednisolone
exposure counted both initial and relapse prednisolone
treatment administered over 24 months. Median follow-up in
months was 36.7 in the 2-month and 38.2 in the 6-month
treatment group. Time to frequent relaps was similar in both
groups; however, the median was reached only in the 6-
month group (799 days). The hazard ratio was 0.86 (90%
confidence interval, 0.64–1.16) and met the non-inferior
margin. Time to first relapse was also similar in both groups:
median day 242 (2-month) and 243 (6-month). Frequency
and severity of adverse events were similar in both groups.
Most adverse events were transient and occurred during
initial or relapse therapy. Thus, 2 months of initial
prednisolone therapy for steroid-sensitive nephrotic
syndrome, despite less prednisolone exposure, is not inferior
to 6 months of initial therapy in terms of time to onset of
frequently relapsing nephrotic syndrome.
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Idiopathic nephrotic syndrome (NS) is a disorder affecting
the kidneys that is mainly characterized by high excretion of
protein in the urine. Pediatric idiopathic NS is understood to
be the most common cause of primary glomerular diseases,
and it frequently occurs in infants aged 2–6 years. Most
patients are presumed to have minor glomerular abnor-
mality. Cellular immunologic abnormalities are believed to
contribute to the condition, although its pathology remains
unknown. In Europe and the United States, two in 100,000
children will develop idiopathic NS in a single year.1 An
8-week corticosteroid regimen is the standard initial treat-
ment for children with idiopathic NS, as outlined by
the International Study of Kidney Disease in Children
(ISKDC).2,3 Although corticosteroids induce the remission
of proteinuria in more than 80% of children with idiopathic
NS, B60% undergo proteinuria relapse. Previous research
has shown that a high number of children undergo frequent
relapse, and corticosteroid toxicities occur after repeated
therapy.2,3 Although some controlled studies4–7 and a meta-
analysis8 show that long-term corticosteroid treatment up to
7 months maximum leads to a longer sustained remission of
NS than ISKDC-recommended administration, the optimum
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dose and duration of initial therapy are still unknown.
A Cochrane review concluded that a well-designed and
adequately powered randomized controlled trial is required
to establish the optimum dose and duration of treatment.8
The purpose of this study is to investigate whether 2 months
of initial prednisolone therapy (ISKDC regimen) is not
inferior to 6 months of initial therapy with an increasing
cumulative dose, and to compare adverse events between
treatment regimens.
RESULTS
Patient population
The study was conducted from September 6, 2007 until
February 8, 2013. Figure 1 shows the trial profile. We assessed
255 patients from 90 hospitals (61 general, 7 children’s, and
22 university hospitals) for eligibility. We randomly assigned
128 patients to the 2-month prednisolone group and 127
patients to the 6-month prednisolone group. We excluded
nine patients from the analysis: six did not receive trial
medication because of either early relapse after remission
during the initial 4-week prednisolone treatment, or with-
drawn consent, and three were excluded owing to a lack of
participant data. Thus, we analyzed data for 246 patients.
Median follow-up was 36.7 months in the 2-month group
(interquartile range 27.8–46.4 months) and 38.2 months in
the 6-month group (interquartile range 28.6–48.5 months).
There was no difference in characteristics between the two
groups (Table 1).
Primary end point
The primary end point was defined as the duration from
start of initial treatment to diagnosis of frequently relapsing
nephrotic syndrome (FRNS), or ‘time to FRNS’. By the end
of the 24-month intervention period, we observed 54 events
in the 2-month group (comprising 46 FRNS [definition 1, 28;
definition 2, 18], and 8 requiring immunosuppressant
administration) and 58 events in the 6-month group
(comprising 45 FRNS [definition 1, 23; definition 2, 22],
and 13 requiring immunosuppressant administration).
Twenty-one patients required immunosuppressants owing
to steroid-dependent or steroid-resistant relapse. Times to
FRNS were similar in both groups: however, the median
duration of time to FRNS was reached only in the 6-month
group (at 799 days). The hazard ratio (HR) was 0.86 (90%
confidence interval (CI), 0.64–1.16; Figure 2), and noninfer-
iority of the 2-month group was confirmed significantly, with
an HR margin of 1.3 (P¼ 0.01). Post-hoc analyses showed
that age groups did not affect the median duration of time to
FRNS. The HRs (95% CI) were 0.92 (0.59–1.45), 0.86
(0.41–1.84), and 0.74 (0.31–1.77) for the age groups 1–5 years,
6–10 years, and 11–15 years, respectively.
Secondary end points
Times to first relapse were similar in both groups: the median
was 242 days and 243 days in the 2-month and 6-month
treatment groups, respectively (HR¼ 0.97; 95% CI,
0.72–1.31; P¼ 0.86; Figure 3). The number of relapses per
person-year during the trial intervention period was 1.25
times in the 2-month group and 1.33 times in the 6-month
group, and the ratio was 0.94 (95% CI, 0.71–1.22; P¼ 0.65,
Table 2). The median cumulative dose of prednisolone
during the 2-year trial period in the 2-month group was
also significantly lower than in the 6-month group (4621.9
[interquartile range¼ 2191.3–7472.5] vs. 6484.8 [inter-
quartile range¼ 3701.0–9577.9], Po0.001).
Adverse events
Frequency and severity of adverse events were similar in both
groups (Table 3). Most adverse events were transient and
occurred during initial therapy or relapse therapy. In our
study, steroid dependency did not greatly affect the occur-
rence of adverse events. Two patients in the 2-month group
had severe adverse events requiring hospitalization. One
patient discontinued because of acute kidney failure during
255 Patients assessed for eligibility
255 Patients randomly assigned
128 Patients assigned to
           2-month prednisolone
127 Patients assigned to
          6-month prednisolone
4 Were excluded:
   3 Early relapse after remission
      during the initial 4-week
       prednisolone
  1 No follow-up data available
124 Patients analyzed 122 Patients analyzed
5 Were excluded:
   2 Early relapse after remission
       during the initial 4-week
       prednisolone
   1 Withdrew consent before
      allocated trial medication
   2 No follow-up data available
Figure 1 | Trial profile.
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relapse (month 10) and recovered in 22 days. Another patient
had pneumonia with influenza infection on the last date
of the 2-month prednisolone treatment and recovered in
10 days. Height standard deviation scores show a significant
decrease in growth at 2 months of follow-up compared with
baseline (Po0.003). In both groups, this was restored within
9 months after initial treatment commenced. Notably, one
patient in the 6-month group was diagnosed with possible
adrenal insufficiency owing to steroid withdrawal according
to clinical symptoms (mild headache and mild nausea) when
the patient switched to trial medication after the initial dose
of prednisolone. Symptoms disappeared on the same day of
onset without further treatment.
DISCUSSION
Extension of initial steroid treatment for more than 3 months
to decrease the risk of relapse in children with steroid-
sensitive (SS) NS has been widely described in previous
studies.4–10 However, 80–90% of children diagnosed with
SSNS who are given new corticosteroid treatments continue
to relapse, and B50% relapse frequently.11 Therefore, initial
approaches to SSNS therapy are likely to be substantially
Table 1 | Baseline characteristics
2-Month prednisolone (n¼ 124) 6-Month prednisolone (n¼ 122) P-value
Male, n (%) 89 (71.8) 87 (71.3) 0.94
Age, mean (s.d.), years 6.7 (4.1) 6.3 (4.1) 0.42
Age group, years
1–5, n (%) 67 (54.0) 66 (54.1) 0.99
6–10, n (%) 33 (26.6) 33 (27.1)
11–15, n (%) 24 (19.4) 23 (18.9)
Blood pressure, mean (s.d.), mmHg
Systolic 104.4 (10.7) 106.4 (12.0) 0.16
Diastolic 62.4 (10.0) 62.5 (11.3) 0.98
Serum albumin, mean (s.d.), g/l 1.4 (0.5) 1.4 (0.5) 0.90
Hospital, n (%)
General 47 (65.3) 46 (64.8) 1.00
Children’s 7 (9.7) 7 (9.9)
University 18 (25.0) 18 (25.4)
Quarterly distribution of disease onset, n (%)
January–March 23 (18.7) 24 (19.7) 0.99
April–June 36 (29.3) 34 (27.9)
July–September 30 (24.4) 31 (25.4)
October–December 34 (27.6) 33 (27.0)
Duration from the first episode to remission, mean (s.d.), days 9.7 (3.1) 10.0 (3.1) 0.45
Abbreviation: s.d., standard deviation.
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
120
124
122
24 36 48
Number at risk
2-Month group
6-Month group
86
82
64
55
34
29
11
14
Time (month)
2-Month prednisolone
6-Month prednisolone
HR for FRNS: 0.86 (90% Cl, 0.64–1.16)
Non-inferiority with HR margin 1.3
of 2-month group: P = 0.01
N
on
- f
re
qu
en
t r
el
ap
se
 ra
te
Figure 2 | Kaplan–Meier estimates of time to frequently relapsing
nephrotic syndrome (FRNS). HR, hazard ratio.
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Figure 3 | Kaplan–Meier estimates of time to first relapse.
HR, hazard ratio.
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different.12 Our results demonstrate that extending initial
steroid treatment, and even increasing the total dose of
prednisolone (2240 vs. 3885mg/m2), does not improve
clinical outcomes (time to FRNS, time to first relapse, the
number of relapses, total prednisolone dose, and adverse
events) for pediatric NS. Our results add to the Cochrane
review by Hodgson et al.8 by comparing treatment regimens
of 2 vs. 6 months.
Our findings build on a 2013 study from the Netherlands.
This well-designed, randomized, double-blind, placebo-con-
trolled trial of children with NS clearly showed no
improvement in clinical outcomes when the initial predni-
solone treatment was extended from 3 to 6 months without
an increasing cumulative dose.13 However, despite the results
of this trial, the most effective duration and dosage of
prednisolone treatment for an initial episode of SSNS is still
under debate.14 Although our study has demonstrated that
increasing the total dose in 2-month or 6-month regimens
does not improve clinical outcomes, further investigation is
still required to determine the most effective duration and
dosage regimen for initial SSNS.
A key strength of our trial is its unique design. This is a
multicenter, randomized, controlled trial for noninferiority
that compares the efficacy of the 2-month ISKDC regimen
with a 6-month, long-term prednisolone regimen. The most
important clinical objective of initial treatment of SSNS is to
prevent frequent relapses. Consequently, the primary end
point was set to time to FRNS rather than initial relapses.
Our data from several analyses consistently support
noninferiority of the ISKDC regimen. In the current trial, a
HR threshold of 1.3 for noninferiority of the primary end
point is slightly high given the feasible study size. However,
the posterior probability that a HR would be smaller than
1.1 and 1.2 (HRs that are commonly used as an upper
equivalence margin) was 91 and 97%, respectively.
In our trial, noninferiority was found in FRNS (primary
end point) and first relapse (secondary end point) between
the ISKDC and 6-month regimens. This means that many
patients relapse even while taking tapering-dose prednisolone
(Figure 3). Previous studies vary in their observation of
(frequent) relapses from either the start or end of initial
therapy.8,13 However, if analyses are performed from the end
of initial therapy, relapses during tapering-dose prednisolone
cannot be counted, possibly resulting in an inadequate
interpretation. Therefore, we selected observations primarily
from the start of initial therapy. In our study design, steroid-
dependent NS was predicted to occur more frequently
because of its definition in the 6-month regimen. This is
one reason why we selected FRNS as a primary end point,
and not steroid-dependent NS. In fact, time to steroid-
dependent NS was significantly higher in the ISKDC regimen
group (data not shown).
No significant difference in adverse events was observed
between the two regimens in our large-scale trial, which is a
similar finding to previous small-scale trials.4–7 Most adverse
events were transient and occurred during initial or relapse
therapy. However, because the ISKDC regimen is generally
less likely to cause adverse events owing to the lower dosage
and the shorter duration, its use can be recommended.
A limitation of our trial is the open-label design, which
may have introduced preconception bias. However, as our
trial design is a noninferiority trial with regular visits, and
relapses are measured objectively, we cannot assume positive
placebo effects. Therefore, the open-label design of this study
may have limited impact on preconception bias. Moreover,
the results of this trial may partially be due to the relatively
high rate of relapse compared with other studies.5 The high
Table 3 | Adverse events during the 24-month trial
intervention perioda
Event
2-Month
prednisolone
n¼ 124
6-Month
prednisolone
n¼ 122 P-value
Hypertensionb 15 9 0.24
Cushingoid appearance
Cushing (moon face)b 54 61 0.46
Central obesityb 20 34 0.052
Striae 1 0 1.00
Adrenal insufficiency 0 1 1.00
Ophthalmological abnormalities
Glaucomab 19 13 0.31
Cataract 0 0
Severe infections
Pneumoniac 1 0 1.00
Peptic ulcer 1 0 1.00
Acute kidney failurec 1 0 1.00
Hyperglycemia 2 3 0.64
Increased laboratory data
ASTb 14 11 0.58
ALTb 26 16 0.14
Amylase 3 0 1.00
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase.
aData are expressed as the number of events.
bMultiple reports were recorded for these adverse events.
cSevere adverse events requiring hospitalization.
Table 2 |Number of relapses
Total number
of relapses
Duration of observation
(person-year)
The number of relapses
(per person-year)
Ratio of the number
of relapses (CI) P-value
2-Month prednisolone 301 240.93 1.25 0.94 0.65
6-Month prednisolone 309 232.62 1.33 (0.71–1.22)
Abbreviation: CI, confidence interval.
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rate of relapse may be owing to our definition of relapse
(proteinuria 2þ or higher). It still remains unknown
whether long prednisolone therapy consisting of a dose of
60mg/m2 per day for 6 weeks, followed by alternate-day
doses of 40mg/m2 per 2 days for 6 weeks, is more effective
against time to FRNS compared with the ISKDC regimen
for treating idiopathic NS. In our study, only one patient
withdrew consent. A low rate of consent withdrawal is
common in Japan.15,16 Cultural differences between countries
may account for variations in rates of consent withdrawal.
In our study, steroid sensitivity was confirmed by day 21
in order to ensure time for eligibility screening. Generally,
remission after 3 weeks is uncommon.17 Therefore, as the
effect of early confirmation of steroid sensitivity was slight,
we decided to confirm steroid sensitivity by day 21.
We conducted a meta-analysis to address the differences
between corticosteroid regimens in children with an initial
episode of SSNS. We searched randomized controlled trials
that compared durations of steroid therapy in children and
reported the number of FRNS cases within 2 years (see the
Supplementary Information online for a detailed search
strategy). Meta-analysis of our study and five studies6,13,18,19
showed a risk ratio (long vs short) of 0.99 (95% CI,
0.68–1.44, see Supplementary Figure 2A online), whereas
meta-analysis of our study and the published studies only
showed an risk ratio of 1.15 (95% CI: 0.95–1.40, Supple-
mentary Figure 2B online). This result might indicate that
long-term treatment is not superior but almost equivalent to
ISKDC-standard therapy.
In conclusion, our study shows that extending initial
prednisolone treatment from 2 to 6 months with an increas-
ing dose does not improve clinical outcomes for pediatric NS.
The original ISKDC regimen is not inferior to 6 months of
initial therapy with an increasing cumulative dose. We assert
that the ISKDC regimen is recommended as an initial
treatment for pediatric idiopathic NS.
MATERIALS AND METHODS
Study design and patients
We conducted a multicenter, randomized, noninferiority, open-label
trial at 90 hospitals in Japan and compared prednisolone treatment
of 2 months (ISKDC regimen) with 6 months for children with
a first episode of idiopathic NS. We diagnosed idiopathic NS and
remission according to the ISKDC.1 NS was defined as a urinary
protein–creatinine ratio X1.8 and albumin levelsp25 g/l in serum.
Remission was defined as a negative dipstick analysis for 3
consecutive days. Patients aged 1–15 years with a first episode of
idiopathic NS were eligible if they had remission within 3 weeks of
prednisolone administration. Patients were ineligible if they had
secondary NS, renal insufficiency defined as creatinine clearance of
p60ml/min per 1.73m2, active infections, poorly controlled
hypertension, severe liver dysfunction, pregnancy, or a history of
immunosuppressant administration.
Before enrollment, patients’ guardians provided written in-
formed consent, and informed assent was obtained from older
children. This study was approved by the institutional review boards
of participating hospitals, complied with the Declaration of Helsinki
and the Declaration of Istanbul, and adhered to the International
Conference on Harmonisation Guidelines on Good Clinical
Practice.
Randomization
Patients were randomly assigned to either the 2-month or 6-month
group in a 1:1 ratio at the Japan Clinical Research Support Unit. We
applied a minimization method using a computer-generated
sequence (SAS PROC PLAN) with age (1–10 years or 11–15 years),
sex, and institution as adjustment (stratification) factors. Patients,
patients’ guardians, treating physicians, and individuals assessing
outcomes and analyzing data were not blinded to the patients’
treatment assignments. Apart from the trial statistician and the
data-monitoring committee, all treating physicians and other
investigators remained blinded to the trial results until follow-up
was completed.
Procedures
The first patient was randomized in September 2007, and the last
patient in January 2011. Follow-up started at diagnosis and was
truncated when the last enrolled patients finished the 24-month
intervention.
All patients diagnosed with a first episode of idiopathic NS
started initial therapy of 60mg/m2 oral prednisolone in three
divided doses (maximum of 80mg/day) daily for 4 weeks. Patients
underwent a screening examination and were registered after their
eligibility, including remission, was verified. Participants switched to
trial medication after initial doses of prednisolone were given
(Figure 4). If participants relapsed after remission during the initial
4-week prednisolone treatment, they were excluded.
Trial medication consisted of initial treatment regimens and
relapse treatment, and was completed within a total of 24 months in
both groups (Figures 4 and 5). The duration of long-term
prednisolone treatment was set to 6 months, which is consistent
with recommendations from a non-Japanese randomized controlled
trial.8 The cumulative dose of initial treatment was 2240mg/m2
(2-month group) and 3885mg/m2 (6-month group). Participants
2-Month prednisolone
Cumulative dose: 2240 mg
6-Month prednisolone
Cumulative dose: 3885 mg
Dose
(Max.)
Week
Dose
(Max.)
Week
60D
(80)
1 – 4
60D
(80)
1 – 4
60AD
(80)
5 – 8
30AD
(40)
13 – 16
15AD
(20)
17 – 20
7–5AD
(10)
21 – 24
40AD
(50)
5 – 8
45AD
(60)
9 – 12
Figure 4 | Initial treatment regimens. Upper doses are in mg/m2
per day. Maximum doses are in mg/day. D, daily; AD, alternate days.
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who relapsed during the 24-month trial medication period received
relapse treatment regimens (Figure 5). Relapse treatment was the
same in both groups. However, relapse treatment given during the
6-month initial treatment was adjusted according to the initial
treatment regimen in the 6-month group.
Participant characteristics (age, sex, physical characteristics,
blood, and urine test results) were recorded at baseline. Clinical
assessment and urine tests (urinalysis, qualitative and quantitative
proteinuria, quantitative creatinine) were performed at 1, 2, 4, and 6
months after enrollment and every 3 months thereafter, and also on
diagnosis of relapse. Blood analysis (complete blood cell count,
blood chemistry) was performed at 1, 2, 6, and 12 months after
enrollment, at the end of treatment, and at diagnosis of relapse only.
Adverse events were recorded throughout the trial period and
assessed using Common Terminology Criteria for Adverse Events
v3.0. Within 4 weeks of starting initial treatment, participants were
screened for glaucoma by an ophthalmologist. Details about
monitoring adverse events are described in the Supplementary
Information online. Briefly, name of diagnosis, severity, seriousness,
date of onset and disappearance, outcome, and assessment of causal
relationship to the study drug were investigated at the start of study
treatment and at 1, 2, 4, 6, 9, 12, 15, 18, 21, and 24 months after the
start of study treatment (each within ±2 weeks).
Outcomes
The primary end point was defined as the duration from start of
initial treatment to diagnosis of FRNS, or ‘time to FRNS’. Diagnosis
of FRNS was based on the relapse dates according to the ISKDC.
In our study, FRNS was defined as two relapses within 6 months
of initial remission (definition 1), or four relapses within any
12-month period (definition 2), which included relapses during
initial tapering treatment but excluded relapses with spontaneous
remissions. Patients were observed for at least 2 years, on the basis of
the Cochrane review, which states that the risk of relapse after 1–2
years was lower after long-term prednisolone treatment relative to
the ISKDC regimen.8 Relapse was defined as proteinuria 2þ or
higher on dipstick analysis for 3 or more consecutive days or
proteinuria 2þ or higher on dipstick analysis and serum albumin
p25 g/l. Immunosuppressant administration was prohibited in the
protocol. However, if administration was undertaken for clinical
necessity, e.g., steroid dependency, it was treated as an event in the
primary analysis. Data for patients who did not experience these
events were considered censored at the last examination. Important
secondary end points were time to first relapse, the number of
relapses per person-year, total prednisolone dose, and adverse events.
Statistical analyses
The primary objective of this trial was to confirm noninferiority of
initial therapy with 2-month treatment compared with 6-month
treatment, with respect to time to FRNS. The noninferiority margin
of HR for the 2-month to 6-month group was predefined to 1.3, and
the significance level was set to 5% (one-sided). The former
was determined based on surveys conducted among practicing
pediatric nephrologists and other specialists before the protocol was
developed.
On the basis of results from a previous study,20 we assumed an
event rate of 15 and 19% at 1 year in the 2- and 6-month groups,
respectively. With a sample size of 125 patients in each treatment
group, an HR test with a one-sided 5% significance level would have
70% power to confirm noninferiority. Accrual and follow-up times
were specified to be 3 and 2 years, respectively.
As the previous study20 was conducted more than 10 years
earlier, it is possible that the current event rate of our study is lower
than the previous study. We scheduled an interim analysis to take
place just before the accrual completion date, which was performed
in October 2010. A statistical test regarding the primary end point
was not performed. The number of events observed matched that of
the assumption, and the study plan was not changed.
Statistical analyses followed the protocol and the intention-
to-treat principle. The Cox proportional hazard model was used
to test noninferiority and estimate the HR with a 90% CI of the
primary end point. The Kaplan–Meier method was used to
summarize time to FRNS. These methods and the log-rank test
were used to analyze time to first relapse. The number of relapses
per person-year was calculated as the total number of relapses
divided by the total observed person-years in each treatment group
(Table 2). A permutation test was used to compare the number of
relapses per person-year between groups. We compared the
prednisolone total dose using the Wilcoxon test. The number of
adverse events was compared using Poisson regression. For baseline
characteristics, we compared distributions of continuous variables
between groups using the t-test or Wilcoxon test, depending on the
shape of the distribution. We analyzed categorical variables using the
chi-squared test or Fisher’s exact test. Posterior probability was
calculated with the improper flat prior and the normal distribution
to which log-HR was approximated. Except for noninferiority
testing of the primary end point, we regarded a two-sided P-value
o0.05 to indicate statistical significance. We analyzed data using
SAS software (version 9.3) and calculated the sample size using the
SAS POWER procedure.
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Figure 5 | Treatment regimens for relapse. aUntil urinary protein is
negative on 3 consecutive days using a urine dipstick test. Upper
doses are in mg/m2/day. A maximum dose of each is the same as
initial treatments in Figure 4. AD, alternate days; D, daily.
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Figure S2. (A) Meta-analysis of studies comparing 2–3 months
of prednisolone to 5–6 months of prednisolone for children with
their first episode of nephrotic syndrome, with an outcome showing
the number of children with frequent relapses after 1–2 years.
(B) Sensitivity analysis excluding Sharma 2002 (unpublished
conference proceeding) from Fig. A.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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APPENDIX
Japanese Study Group of Kidney Disease in Children (JSKDC).
JSKDC has been supported by grants from the Ministry of
Health, Labour and Welfare, Japan. Members of the JSKDC
are as follows.
Steering Committee:Norishige Yoshikawa (chair), Kazumoto
Iijima, Hidefumi Nakamura, Masataka Honda, and Mayumi
Sako.
JSKDC study office: Koichi Nakanishi (chair) and Yuko
Shima.
Data Coordinating Center: Yasuo Ohashi (chair).
Statistical Center: Mari S Oba (chair).
Data and Safety Monitoring Board: Takashi Igarashi, Yasuo
Ohashi, Tetsuya Kawamura, and Michio Nagata.
Clinical Investigators (Institution): Satoshi Sasaki (Hokkai-
do University Hospital), Yutaka Yamada (Hakodate Central
General Hospital), Tetsuro Nagashima (Kushiro Red Cross
Hospital), Yoshinori Saita (Japanese Red Cross Kitami
Hospital), Tetsuji Morimoto (Tohoku University Hospital),
Yohei Ikezumi (Niigata University Medical & Dental
Hospital), Toshio Yanagihara (Niigata Prefecture Yoshida
Hospital), Noriko Oonishi (Fujita General Hospital), Tomoko
Sato (Jusendo General Hospital), Kenji Nemoto (Shirakawa
Kosei General Hospital), Katsutoshi Nagasawa (Takeda
General Hospital), Masahiko Katayose (Public Soma General
Hospital), Yoshiyuki Namai (Ohta General Nishinouchi
Hospital), Shigeo Suzuki (Ohara General Hospital), Yasuaki
Kobayashi (Japanese Red Cross Ashikaga Hospital), Yoko
Owada (Dokkyo Medical University Hospital), Hideaki
Kurayama (National Hospital Organization Chiba-East-Hos-
pital), Shuichiro Fujinaga (Saitama Children’s Medical
Center), Midori Awazu (Keio University Hospital), Hirotaka
Takahashi (Tokyo Metropolitan Ohtsuka Hospital), Shori
Takahashi (Surugadai Nihon University Hospital), Motoshi
Hattutori (Tokyo Women’s Medical University Hospital),
Shuichi Ito and Koichi Kamei (National Center for Child
Health and Development), Masayasu Ohta (Toride Kyodo
General Hospital), Tae Omori (Tokyo Metropolitan Bokutoh
Hospital), Nobuyuki Kurosawa (Tsuchiura Kyodo General
Hospital), Masuhiro Shimoda (Japanese Red Cross Musashino
Hospital), Shiro Tsuchiya (Soka Municipal Hospital),
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Masami Shirai (Iwata City Hospital), Kozo Muto (Shimada
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